Use of immunomodulatory drugs in patients with eye disorders, Granma 2017-2020

Background: the torpid progress of chronic eye disorders, with conventional treatments, impels the alternative use of immunomodulators.Objective: to describe the use of immunomodulators in patients with chronic eye disorders that do not improve with conventional treatments, attended to at the department of immunoallergy of the Clinic of Medical Specialties of Granma, from 2017 through 2020.Methods: a descriptive study was carried out at the aforementioned clinic and during the period herein declared. Out of a universe of 101 patients, older than 18 years, 96 were chosen by intentional sampling who consented to be treated with immunomodulators, from January 2017 through December 2018, with follow-ups of at least two-year duration. The effectiveness of immunomodulators on keratitis and uveitis was studied. The following drugs were used: Hebertrans, human gamma globulins at 10 % and the combination of this with levamisole or Hebertrans.Results: treatments were effective in 89,58 % of overall cases, reaching 92,86 % in posterior uveitis. Ten patients could not be controlled, half of them with herpetic keratitis. 61,46 % were treated with Hebertrans, which was effective in 89,83 %. 87,46 % of the patients with herpetic keratitis were controlled with Hebertrans and 90,91 % of the patients suffering from uveitis with human gamma globulins.Conclusions: the use of immunomodulators in patients with chronic eye disorders was described. Hebertrans, single gamma globulin or its combinations were effective.